SCHEMBL3514520

SCHEMBL3514520

COc1ccc(C([NH])=O)c(OC)c1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
TUBB1 Q9H4B7 3/20 0.48
PDE4D Q08499 2/20 0.48
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
ALDH1A1 P00352 2/20 0.47
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CYP1A1 P04798 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP1B1 Q16678 1/20 0.44
PKM P14618 1/20 0.44
CASP3 P42574 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
ABCG2 Q9UNQ0 1/20 0.44
MCL1 Q07820 2/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9726919 0.83 MAPT (0.58) MAPTTDP1TUBB1PDE4DMEN1
SCHEMBL3556531 0.82 NPC1 (0.53) MAPTMEN1KMT2AALDH1A1NPC1
SCHEMBL102827 0.82 MAPT (0.72) MAPTTDP1TUBB1PDE4DMEN1
SCHEMBL1421887 0.82 ALDH1A1 (0.59) MAPTTDP1TUBB1PDE4DMEN1
SCHEMBL4913002 0.82 MAPT (0.56) MAPTTDP1TUBB1PDE4DMEN1
SCHEMBL30069060 0.82 ALDH1A1 (0.59) MAPTTDP1TUBB1PDE4DMEN1
Methyl 2,3,4-Trimethoxybenzoate SCHEMBL1434191 0.80 ALDH1A1 (0.57) MAPTTDP1TUBB1PDE4DMEN1
Hydrochloric Acid SCHEMBL5061862 0.80 MAPT (0.70) MAPTTDP1TUBB1PDE4DMEN1
SCHEMBL8526786 0.80 MAPT (0.55) MAPTTDP1TUBB1PDE4DMEN1
SCHEMBL4638173 0.80 MAPT (0.55) MAPTTDP1TUBB1PDE4DMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305113-A1 Substituted Imidazopyridazines as Lipid Kinase Inhibitors CAPRARO HANS-GEORG 2010-12-02 US disclosed
EP-2155753-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS Novartis Ag (CH) 2010-02-24 EP disclosed
WO-2008138834-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AS PI3K LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-11-20 WO disclosed
EP-0183191-B1 THIENYLTHIAZOLE COMPOUNDS Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1989-05-10 EP disclosed
US-4720493-A Thienylthiazole compounds YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1988-01-19 US disclosed
EP-0183191-A1 Thienylthiazole compounds Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1986-06-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305113-A1 Substituted Imidazopyridazines as Lipid Kinase Inhibitors PI4KA, PIK3CA, PIK3CB MAPT 4503/4885TDP1 1603/4885TUBB1 3856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.